Effects of a Tph1 inhibitor and of a CO-releasing molecule on experimental pulmonary hypertension
La diminution de la biodisponibilité de la sérotonine (5-HT) en inhibant sa biosynthèse peut représenter un traitement complémentaire efficace de l'hypertension artérielle pulmonaire (HTAP). Nous avons évalué cette hypothèse en utilisant LP533401, qui inhibe la tryptophane hydroxylase 1 (TPH1),...
Main Author: | Abid, Shariq |
---|---|
Other Authors: | Paris Est |
Language: | fr |
Published: |
2013
|
Subjects: | |
Online Access: | http://www.theses.fr/2013PEST0064 |
Similar Items
-
Whole blood donor deferral analysis at a center in Western India
by: Agnihotri Naveen
Published: (2010-01-01) -
Investigation of Predictive Potential of TPH1 Common Polymorphism in Idiopathic Scoliosis
by: Svetla Todorova Nikolova, et al.
Published: (2016-09-01) -
Hypertension in Related Living Donor Renal Allograft Recipients
by: Sqalli Tarik, et al.
Published: (2008-01-01) -
Effectiveness of blood donor questionnaire directed at risk factor for transfusion transmitted infections in Pakistani population
by: Nuzhat Salamat
Published: (2012-01-01) -
Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report
by: Takashi Onoe, et al.
Published: (2018-02-01)